Article: Bionano Genomics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

Article - Media, Publications

Bionano Genomics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

GLOBE NEWSWIRE, 23 March 2021

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results and business achievements for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate updates.

“2020 was an important momentum-building year for Bionano and one that allowed us to showcase many of our strengths. Despite 2020’s challenges, we executed well on our commercial offerings for Saphyr® by expanding the number of systems in the field and the number of samples analyzed in our data services lab. We believe this progress helped create the awareness needed to develop the market for structural variation analysis and optical genome mapping, or OGM, furthering our goal of disrupting the genomics industry,” said Erik Holmlin, PhD, CEO of Bionano. “2021 is shaping up to be a transformational year for the company. Continue reading “Article: Bionano Genomics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates”

Article: Form 8-K Bionano Genomics, Inc

Article - Media, Publications

Form 8-K Bionano Genomics, Inc/strong>

EDGARFILINGS LTD, 21 January 2021

On January 20, 2021, Bionano Genomics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc., as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 33,333,350 shares of the Company’s common stock, par value $0.0001 per share. The price to the public in the offering is $6.00 per share and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $5.64 per share. The net proceeds to the Company from the offering are expected to be approximately $187.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The closing of the offering is expected to occur on January 22, 2021, subject to customary closing conditions. In addition, the Company granted the Underwriters a 30-day option to purchase up to 5,000,002 shares of the Company’s common stock at the public offering price, less the underwriting discounts and commissions. Continue reading “Article: Form 8-K Bionano Genomics, Inc”

Article: Form 424B5 Bionano Genomics, Inc

Article - Media, Publications

Form 424B5 Bionano Genomics, Inc

EDGARFILINGS LTD, 07 January 2021

Common Stock We are offering shares of our common stock at a purchase price of $ per share pursuant to this prospectus supplement. Our common stock is listed on the Nasdaq Capital Market under the symbol “BNGO.” On January 6, 2021, the last reported sale price of our common stock was $4.77 per share. We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus supplement and may elect to do so in future filings. Our business and an investment in our securities involve significant risks. These risks are described under the caption “Risk Factors” beginning on page S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.

Read Full Article

Article: Exuberance Over Good News Drives Bionano Genomics’ Wild Week

Article - Media, Publications

Exuberance Over Good News Drives Bionano Genomics’ Wild Week

John Alford, 04 January 2021

Bionano Genomics, Inc. (BNGO) has been on a wild, meteoric rise in the past few days, and after hours on the 31st it continued to skyrocket, rising to $4 a share. On the 31st of December alone, counting market and after-hours trading, share prices surged $1.90, almost doubling. This capped a wild week, and is a momentum-driven mania trade not based on the previous performance or long-term trend of the company. While recently reporting one good report (via a paid PR service), there are obvious issues surrounding the company to the investor that takes the time to evaluate their most recent 10-Q, recent and potential massive dilution, and decreasing revenue. Continue reading “Article: Exuberance Over Good News Drives Bionano Genomics’ Wild Week”

Article: BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING

Article - Media, Publications

BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING

GLOBE NEWSWIRE, 02 April 2020

BIONANO GENOMICS, INC. (BNGO), a genome analysis company that provides tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing, today announced the pricing of an underwritten public offering of 54,546,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and common warrants to purchase up to an aggregate of 54,546,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.33 per share and accompanying common warrant. For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis. Continue reading “Article: BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING”

Article: Form S-1/A Bionano Genomics, Inc

Article - Media, Publications

Form S-1/A Bionano Genomics, Inc

EDGARFILINGS LTD, 17 October 2020

We are offering 5,265,000 shares of our common stock and common warrants to purchase an aggregate of 5,265,000 shares of our common stock (and the shares of common stock that are issuable from time to time upon exercise of the warrants). We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. Continue reading “Article: Form S-1/A Bionano Genomics, Inc”

Article: Bionano Genomics : SEC Filing (424B3) – Supplemental Prospectus

Article - Media, Publications

Bionano Genomics : SEC Filing (424B3) – Supplemental Prospectus

MarketScreener, 20 March 2020

This prospectus covers the offer and resale by Innovatus Life Sciences Lending Fund I, LP, or Innovatus, and Innovatus Life Sciences Offshore Fund I-A, LP, or Innovatus Offshore, of up to an aggregate of 1,141,408 shares of our common stock, which includes 161,987 shares of our common stock issuable upon the exercise of warrants, issued to Innovatus and Innovatus Offshore in private transactions. Innovatus and Innovatus Offshore are also collectively referred to in this prospectus as the selling stockholders.

We are not selling any shares of common stock under this prospectus and will not receive any of the proceeds from the sale by the selling stockholders of such shares. Continue reading “Article: Bionano Genomics : SEC Filing (424B3) – Supplemental Prospectus”

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?